COVID-19, immunocompromised host, dual anti-SARS-CoV-2 therapies, combination therapy, prolonged viral shedding, individualized therapeutic approaches
immunodeficiency, Omicron, SARS-CoV-2, BA.1, sotrovimab, escape mutations
Adaptive natural killer cells, antibody-dependent cellular cytotoxicity, chronic hepatitis B, HBV/HDV coinfection, human cytomegalovirus
COVID-19, Post-acute COVID-19 syndrome, Fatigue, Cognitive dysfunction, Longitudinal studies, Trajectory, Prospective cohort, growth mixture models